76
Participants
Start Date
March 28, 2014
Primary Completion Date
December 31, 2020
Study Completion Date
June 30, 2023
Adavosertib
Given PO
Irinotecan Hydrochloride
Given PO
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Parnassus, San Francisco
UCSF Medical Center-Mission Bay, San Francisco
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Hospital for Sick Children, Toronto
National Cancer Institute (NCI)
NIH